Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Unintentional platelet removal by plasmapheresis.

J J Perdue1, L K Chandler, S K Vesely

  • 1Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA.

Journal of Clinical Apheresis
|December 18, 2001
PubMed
Summary

Therapeutic plasmapheresis can unintentionally remove platelets, potentially leading to misdiagnosis. Different apheresis instruments show significant variations in platelet loss during treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry.

Hamostaseologie·2013
Same author

The Oklahoma Thrombotic Thrombocytopenic Purpura-haemolytic Uraemic Syndrome Registry. A model for clinical research, education and patient care.

Hamostaseologie·2013
Same author

Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP).

Journal of thrombosis and haemostasis : JTH·2010
Same author

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder.

Bone marrow transplantation·2008
Same author

Management of patients with refractory immune thrombocytopenic purpura.

Journal of thrombosis and haemostasis : JTH·2006
Same author

An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura.

Journal of thrombosis and haemostasis : JTH·2006

Area of Science:

  • Hematology
  • Nephrology
  • Transfusion Medicine

Background:

  • Therapeutic plasmapheresis is used to treat various conditions by removing plasma.
  • Unrecognized platelet loss during apheresis can complicate patient assessment and treatment.
  • A case of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) highlighted potential issues with persistent thrombocytopenia interpretation.

Observation:

  • A systematic study investigated platelet loss during plasmapheresis procedures.
  • Data were collected from 432 apheresis procedures across 71 patients and six disease categories.
  • Three different apheresis instruments were evaluated for their impact on platelet counts.

Findings:

  • Significant differences in platelet loss were observed among apheresis instruments (P<0.001).

Related Experiment Videos

  • The Fresenius AS 104 resulted in greater platelet loss (17.5%) compared to COBE Spectra (1.6%) and Haemonetics LN9000 (2.6%).
  • Patients with dysproteinemias treated for hyperviscosity experienced higher platelet loss.

    • Implications:

    • Accurate assessment of platelet counts is crucial during plasmapheresis to avoid misinterpreting apheresis-induced thrombocytopenia as active disease.
    • Instrument selection in plasmapheresis may influence the degree of platelet removal.
    • Further research is needed to optimize apheresis protocols to minimize unintended platelet loss.